[ad_1]
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Will Charlton, MD, MAS, has been appointed Chief Medical Officer, and will succeed Rosh Dias, MD, who has stepped down to pursue other opportunities. Dr. Charlton is a board-certified pediatric endocrinologist with over 15 years of clinical research experience in industry and academia and will lead the company’s clinical development and global drug development strategy.
“We are pleased to welcome Will as our Chief Medical Officer, and we look forward to his leadership and guidance as we continue to advance our pipeline of treatments for patients with rare endocrine disorders,” said Javier Szwarcberg, MD, MPH, Chief Executive Officer of Spruce Biosciences. “With his extensive background in late-stage rare disease drug development, paired with his experience as a board-certified endocrinologist, we are confident that Will’s expertise will be a strong asset to Spruce as we progress tildacerfont through clinical development for adults and children with classic congenital adrenal hyperplasia and women with polycystic ovary syndrome.”
Dr. Will Charlton is an accomplished physician-scientist with nearly two decades of experience as a clinician and industry executive building successful programs across clinical development, medical affairs and drug safety. He joins Spruce from 89bio, Inc., where he served as Vice President , Clinical Development. Prior to 89bio, he was Senior Medical Director, Clinical Development at Ascendis Pharma. Prior …
Full story available on Benzinga.com
[ad_2]
Source link
